Maze Therapeutics
MAZE · Nasdaq · United States
Share price · MAZE
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when MAZE's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 22 Sep 2026+26.8%
Nothing announced by MAZE that day or the session before.
- 9 Sep 2026-6.8%
Nothing announced by MAZE that day or the session before.
- 10 Aug 2026-4.8%
Nothing announced by MAZE that day or the session before.
- 16 Jul 2026-7.6%
Nothing announced by MAZE that day or the session before.
- 25 Mar 2026-35.2%
- 10 Mar 2026+13.3%
Nothing announced by MAZE that day or the session before.
- 20 Jan 2026+8.8%
Nothing announced by MAZE that day or the session before.
- 18 Dec 2025+5.8%
Nothing announced by MAZE that day or the session before.
Share of unusual movement by asset
For each asset, the share of MAZE's own-move activity since 3 Feb 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
MZE829events and moves
| 2 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 13% |
| Other company news (earnings, financing, releases naming no asset) | — | 26% |
| Sessions with no dated event | — | 61% |
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | APOL1 (Apolipoprotein L1)Small molecule | Chronic Kidney Disease |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (9)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | $40M | $155M+ $236M short-term inv. | $48M-$33M operating cash flow | report ↗ |
View 8 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $35M | $204M+ $208M short-term inv. | $45M-$15M operating cash flow | report ↗ |
| 2026-Q1 | $20M | $34M | $200M+ $154M short-term inv. | $24M-$39M operating cash flow | report ↗ |
| 2025-Q3 | — | $25M | $318M+ $67M short-term inv. | $30M-$25M operating cash flow | report ↗ |
| 2025-Q2 | $0 | $28M | $266M | $34M-$30M operating cash flow | report ↗ |
| 2025-Q1 | — | $28M | $295M | $33M-$30M operating cash flow | report ↗ |
| 2024-Q3 | $2.5M | $20M | $151M | $25M-$23M operating cash flow | report ↗ |
| 2024-Q2 | $165M | $20M | $176M | —$145M operating cash flow | report ↗ |
| 2024-Q1 | — | $22M | $31M | $32M-$23M operating cash flow | report ↗ |
Annual history (3 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $108M | $190M+ $153M short-term inv. | $33M-$112M operating cash flow | report ↗ |
For fiscal 2025, Maze Therapeutics recognized no license revenue, versus $167.5M in 2024, while R&D expense was $108.4M, up 29.9% YoY from $83.5M. Cash, cash equivalents and marketable securities totaled $360.0M at December 31, 2025, compared with $196.8M at the end of 2024. The company reported a net loss of $131.1M for the year, after net income of $52.2M in 2024.
The company announced positive topline data from the Phase 2 HORIZON trial of MZE829, showing a 35.6% mean reduction in uACR at week 12 in broad AMKD patients, and plans to advance MZE829 into a pivotal program while continuing enrollment. Two Phase 2 proof-of-concept trials of MZE782 in PKU and CKD are expected to initiate by mid-2026 and in the second half of 2026, respectively. Maze also appointed Neil Kumar to its board of directors and earned a $20M milestone from Shionogi related to first-patient dosing in the ESPRIT Phase 2 trial of MZE001. Management expects its current cash position to fund operations into 2028.
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 100 sales ($25.0M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-02 | Coloma Jason V · director, Chief Executive Officer | Open-market sale | 2,257 | $30.12 | $68K | Form 4 |
| 2026-11-02 | Coloma Jason V · director, Chief Executive Officer | Open-market sale | 336 | $30.91 | $10K | Form 4 |
| 2026-11-02 | Coloma Jason V · director, Chief Executive Officer | Open-market sale | 26,563 | $30.09 | $799K | Form 4 |
| 2026-11-02 | Coloma Jason V · director, Chief Executive Officer | Open-market sale | 5,345 | $31.05 | $166K | Form 4 |
| 2026-10-29 | Dandekar Atul · CSBO | Option exercise | 6,643 | $10.42 | $69K | Form 4 |
| 2026-10-29 | Dandekar Atul · CSBO | Option exercise | 857 | $10.42 | $9K | Form 4 |
| 2026-10-29 | Dandekar Atul · CSBO | Open-market sale | 7,500 | $32.07 | $241K | Form 4 |
| 2026-10-29 | Dandekar Atul · CSBO | Option exercise (derivative) | 6,643 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 165 reporting institutions held 51.7M shares ($1.5B, 94.5% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | Frazier Life Sciences Management, L.P. | 4,567,274 | $136.3M |
| 2 | TRV GP IV, LLC | 4,473,958 | $133.5M |
| 3 | ARCH Venture Management, LLC | 4,120,053 | $123.0M |
| 4 | Deep Track Capital, LP | 3,477,562 | $103.8M |
| 5 | JANUS HENDERSON GROUP PLC | 2,858,876 | $85.3M |
| 6 | Paradigm Biocapital Advisors LP | 2,744,399 | $81.9M |
| 7 | BlackRock, Inc. | 2,570,425 | $76.7M |
| 8 | a16z Capital Management, L.L.C. | 1,702,225 | $50.8M |
| 9 | Venrock Adviser, LLC | 1,602,034 | $47.8M |
| 10 | VANGUARD CAPITAL MANAGEMENT LLC | 1,435,656 | $42.9M |
| 11 | Alphabet Inc. | 1,388,583 | $41.4M |
| 12 | Logos Global Management LP | 1,235,000 | $36.9M |
| 13 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 1,178,000 | $35.2M |
| 14 | General Catalyst Group Management, LLC | 1,035,910 | $30.9M |
| 15 | TRV GP V, LLC | 950,800 | $28.4M |